Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan
Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan
复制标题
DOI：
10.1111/1756-185x.13974
复制
发表时间：
2020-10-05
影响因子：
2.5
通讯作者：
Harigai, Masayoshi
中科院分区：
文献类型：
--
作者：
Nakajima, Ayako;Sakai, Ryoko;Harigai, Masayoshi
目的了解日本类风湿关节炎（RA）的患病率、年龄分层治疗趋势和临床特征。方法采用7种RA定义，利用日本国家健康保险理赔和特定健康检查数据库，估算2017财年bb0 = 16岁人群RA患病率。我们分析了特征和治疗的年龄分层趋势。结果1116122例年龄bb0 = 16岁且至少有1例RA相关的国际疾病分类-10代码的患者中，8257000例（女性，76.3%）被评估为RA，估计患病率为0.65%。70-79岁患者的年龄分层患病率最高，为1.63%。总体而言，60.8%和7.0%的RA患者年龄分别为>= 65岁和>= 85岁。50-59岁患者使用甲氨蝶呤最多（73.0%），50- 85岁患者使用甲氨蝶呤最少（38.2%）。16-19岁患者使用生物疾病缓解类抗风湿药物的比例为50.9%，而85岁患者则降至13.7%。在16-19岁和>= 85岁的患者中，肿瘤坏死因子抑制剂与阿巴接受的使用偏好分别从24.0∶1下降到1.7∶1。60 ~ 69岁患者心血管疾病患病率为3.5%，85岁患者心血管疾病患病率为12.1%。总体而言，ra相关的骨科手术在70-79岁的患者中最为普遍。结论日本RA患者患病率为0.65%。年龄分层的治疗趋势和临床特点已被描述在一个超高龄的社会首次。
Aim To estimate the prevalence and age-stratified treatment trends and clinical characteristics of rheumatoid arthritis (RA) in Japan. Method Using 7 RA definitions, the prevalence of RA in those aged >= 16 years was estimated using the National Database of Health Insurance Claims and Specific Health Checkups of Japan in the fiscal year 2017. We analyzed age-stratified trends in characteristics and treatments. Results Of 1 116 122 patients aged >= 16 years with at least 1 RA-related International Classification of Diseases-10 code, 825.7 thousand patients (women, 76.3%) were assessed as having RA with an estimated prevalence of 0.65%. The highest age-stratified prevalence was 1.63% in patients aged 70-79 years. Overall, 60.8% and 7.0% of patients with RA were aged >= 65 years and >= 85 years, respectively. Methotrexate use was most frequent in patients aged 50-59 years (73.0%) and least frequent in patients aged >= 85 years (38.2%). Biologic disease-modifying antirheumatic drugs use was 50.9% in patients aged 16-19 years and decreased to 13.7% in those aged >= 85 years. Preference for the use of tumor necrosis factor inhibitors versus abatacept decreased from 24.0:1 to 1.7:1 in patients aged 16-19 years and >= 85 years, respectively. The prevalence of cardiovascular disease was 3.5% in patients aged 60-69 years and 12.1% in those aged >= 85 years. Overall RA-related orthopedic surgeries were most prevalent in patients aged 70-79 years. Conclusion The estimated prevalence of patients with RA in Japan was 0.65%. Age-stratified treatment trends and clinical characteristics have been described in a super-aged society for the first time.